Discovery of 4,6-pyrimidinediamine derivatives as novel dual EGFR/FGFR inhibitors aimed EGFR/FGFR1-positive NSCLC-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Discovery of 4,6-pyrimidinediamine derivatives as novel dual EGFR/FGFR inhibitors aimed EGFR/FGFR1-positive NSCLC

Published:2020-02 Issue: Volume:187 Page:111943
ISSN:0223-5234
Container-title:European Journal of Medicinal Chemistry
language:en
Short-container-title:European Journal of Medicinal Chemistry

Author:

Xie Zixin,Wu Kaiqi,Wang Yuexuan,Pan Yaqian,Chen Bo,Cheng Donghua,Pan Suwei,Guo Taoning,Du Xuze,Fang Longcheng,Wang Xuebao,Ye Faqing

Funder

National Natural Science Foundation of China

Natural Science Foundation of Zhejiang Province

National Natural Science Foundation of Zhejiang Province

Publisher

Elsevier BV

Subject

Organic Chemistry,Drug Discovery,Pharmacology,General Medicine

Reference25 articles.

1. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy;Paez;Science,2004

2. Treatments for EGFR-mutant non-small cell lung cancer (NSCLC): the road to a success, paved with failures;Lee;Pharmacol. Ther.,2017

3. Resistance to EGFR inhibitors in non-small cell lung cancer: clinical management and future perspectives;Tomasello;Crit. Rev. Oncol.-Hematol.,2018

4. Treatment approaches for EGFR-inhibitor-resistant patients with non-small-cell lung cancer;Tan;Lancet Oncol.,2015

5. Analysis of tumor specimens at the time of acquired resistance to EGFR-TKI therapy in 155 patients with EGFR-mutant lung cancers;Yu;Clin. Cancer Res.,2013

Cited by 20 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Discovery of a prominent dual-target DDR1/EGFR inhibitor aimed DDR1/EGFR-positive NSCLC;Bioorganic Chemistry;2024-08

2. From clinical management to personalized medicine: novel therapeutic approaches for ovarian clear cell cancer;Journal of Ovarian Research;2024-02-12

3. Design, synthesis and antitumor activity of 4-arylamine substituted pyrimidine derivatives as noncovalent EGFR inhibitors overcoming C797S mutation;European Journal of Medicinal Chemistry;2024-02

4. Epidermal growth factor receptor dual-target inhibitors as a novel therapy for cancer: A review;International Journal of Biological Macromolecules;2023-12

5. KinomeMETA: meta-learning enhanced kinome-wide polypharmacology profiling;Briefings in Bioinformatics;2023-11-22

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3